Literature DB >> 29203837

Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma.

Joaquim Bellmunt1, Rosa Nadal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29203837     DOI： 10.1038/nrclinonc.2017.184

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

Authors:  Daniel P Petrylak; Scott T Tagawa; Manish Kohli; Andrea Eisen; Christina Canil; Srikala S Sridhar; Alexander Spira; Evan Y Yu; John M Burke; David Shaffer; Chong-Xian Pan; Jenny J Kim; Jeanny B Aragon-Ching; David I Quinn; Nicholas J Vogelzang; Shande Tang; Hui Zhang; Christopher T Cavanaugh; Ling Gao; John S Kauh; Richard A Walgren; Kim N Chi
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

2.  Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Authors:  Daniel P Petrylak; Ronald de Wit; Kim N Chi; Alexandra Drakaki; Cora N Sternberg; Hiroyuki Nishiyama; Daniel Castellano; Syed Hussain; Aude Fléchon; Aristotelis Bamias; Evan Y Yu; Michiel S van der Heijden; Nobuaki Matsubara; Boris Alekseev; Andrea Necchi; Lajos Géczi; Yen-Chuan Ou; Hasan Senol Coskun; Wen-Pin Su; Miriam Hegemann; Ivor J Percent; Jae-Lyun Lee; Marcello Tucci; Andrey Semenov; Fredrik Laestadius; Avivit Peer; Giampaolo Tortora; Sufia Safina; Xavier Garcia Del Muro; Alejo Rodriguez-Vida; Irfan Cicin; Hakan Harputluoglu; Ryan C Widau; Astra M Liepa; Richard A Walgren; Oday Hamid; Annamaria H Zimmermann; Katherine M Bell-McGuinn; Thomas Powles
Journal:  Lancet       Date:  2017-09-12       Impact factor: 79.321

3.  Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Authors:  Joaquim Bellmunt; Ronald de Wit; David J Vaughn; Yves Fradet; Jae-Lyun Lee; Lawrence Fong; Nicholas J Vogelzang; Miguel A Climent; Daniel P Petrylak; Toni K Choueiri; Andrea Necchi; Winald Gerritsen; Howard Gurney; David I Quinn; Stéphane Culine; Cora N Sternberg; Yabing Mai; Christian H Poehlein; Rodolfo F Perini; Dean F Bajorin
Journal:  N Engl J Med       Date:  2017-02-17       Impact factor: 91.245

4.  Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

Authors:  Atreya Dash; Matthew D Galsky; Andrew J Vickers; Angel M Serio; Theresa M Koppie; Guido Dalbagni; Bernard H Bochner
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

5.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

6.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Authors:  Arjun V Balar; Daniel Castellano; Peter H O'Donnell; Petros Grivas; Jacqueline Vuky; Thomas Powles; Elizabeth R Plimack; Noah M Hahn; Ronald de Wit; Lei Pang; Mary J Savage; Rodolfo F Perini; Stephen M Keefe; Dean Bajorin; Joaquim Bellmunt
Journal:  Lancet Oncol       Date:  2017-09-26       Impact factor: 41.316
  6 in total
  2 in total

1.  SLC14A1 (UT-B) gene rearrangement in urothelial carcinoma of the bladder: a case report.

Authors:  Zhongying Guo; Xiaobing Niu; Guangbo Fu; Baoxue Yang; Guangping Chen; Su'an Sun
Journal:  Diagn Pathol       Date:  2020-07-23       Impact factor: 2.644

2.  Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma.

Authors:  Fangfang Liang; Yansong Xu; Yi Chen; Huage Zhong; Zhen Wang; Tianwen Nong; Jincai Zhong
Journal:  Front Mol Biosci       Date:  2021-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.